Pathstone Holdings
BIO icon

Pathstone Holdings’s Bio-Rad Laboratories Class A BIO Stock Holding History

Pathstone Holdings’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$661K Sell
2,251
-187
-8% -$53K ﹤0.01% 1725
2026
Q1 		$680K Sell
2,438
-174
-7% -$50.1K ﹤0.01% 1607
2025
Q4 		$791K Sell
2,612
-104
-4% -$32.5K ﹤0.01% 1538
2025
Q3 		$762K Buy
2,716
+516
+23% +$140K ﹤0.01% 1561
2025
Q2 		$531K Sell
2,200
-464
-17% -$110K ﹤0.01% 1699
2025
Q1 		$653K Buy
2,664
+284
+12% +$85.4K ﹤0.01% 1588
2024
Q4 		$782K Buy
2,380
+129
+6% +$43.8K ﹤0.01% 1489
2024
Q3 		$753K Sell
2,251
-119
-5% -$37.8K ﹤0.01% 1514
2024
Q2 		$647K Sell
2,370
-1,649
-41% -$480K ﹤0.01% 1560
2024
Q1 		$1.39M Buy
4,019
+1,300
+48% +$427K 0.01% 1083
2023
Q4 		$878K Buy
+2,719
New +$852K ﹤0.01% 1145

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Pathstone Holdings's BIO Position: Q2 2026 in Review

Pathstone Holdings reduced its Bio-Rad Laboratories Class A (BIO) stake by 7.7% in Q2 2026, selling an estimated $53K and leaving 2,251 shares worth $661K. The position accounts for ﹤0.01% of the portfolio, ranked #1725.

Pathstone Holdings first reported a position in BIO in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.39M in Q1 2024. 397 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Pathstone Holdings held 2,251 shares of Bio-Rad Laboratories Class A worth $661K as of Q2 2026.
  • Pathstone Holdings sold 187 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $53K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #1725 holding.
  • Pathstone Holdings first reported a position in Bio-Rad Laboratories Class A in Q4 2023 and has held it in 11 quarters since.
  • Pathstone Holdings's Bio-Rad Laboratories Class A position peaked at $1.39M in Q1 2024.
  • 397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.